Abstract
The recent US Food and Drug Administration approval of an integrated real-time continuous glucose monitoring (CGM) system and insulin pump (Medtronic Mini-Med Paradigm REAL-Time System; Medtronic MiniMed, Inc., Northridge, Calif) is the most recent breakthrough paving the way toward the development of a closedloop insulin delivery system that could revolutionize diabetes care. An early prototype of the MiniMed Paradigm REAL-Time System—which provided both realtime CGM and insulin pump therapy but was not yet fully integrated—was tested in 20 volunteer subjects with type 1 diabetes who wore the device for up to 2 y. Subjects were instructed on the technical use of the device but were provided no additional support, aside from their usual diabetes care. Participation in the trial averaged 317 d (minimum, 88 d; maximum, 618 d). Five participants prematurely dropped out of the study (2 because of the inconvenience of carrying 2 devices). Data from all subjects were analyzed. Subjects reduced their A1C by a mean of 1.1% (standard deviation, 0.8). After 3 mo of device use, the number of participants who achieved A1C <7% increased by more than 3-fold. Individuals with baseline A1C ≥7% had a 67% likelihood of achieving an A1C <7% by the first follow-up assessment. This observational study of combined CGM and insulin pump therapy suggests that this innovative device can help people achieve improved glycemic control. Given that only about one third of individuals with diabetes are achieving glycemic control targets, more effective methods to help patients avoid the devastating consequences of uncontrolled diabetes are desperately needed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cleary P. The FDA selects the development of an artificial pancreas as a critical path opportunity: JDRF praises the FDA for supporting technology that will revolutionize diabetes care. Juvenile Diabetes Research Foundation International Web site. Available at: http://www.jdrf.org/index.cfm? page_id=104778. Accessed April 27, 2006.
Tavris DR, Shoaibi A. The public health impact of the MiniMed Continuous Glucose Monitoring System (CGMS)—an assessment of the literature.Diabetes Technol Ther. 2004; 6: 518–522.
Bode B, Gross K, Rikalo N, et al. Alarms based on real-time sensor glucose values alert patients to hypo and hyperglycemia: the Guardian Continuous Monitoring System.Diabetes Technol Ther. 2004; 6: 105–113.
US Food and Drug Administration. Guardian RT—P980022s011. FDA, Center for Devices and Radiological Health Web site. Available at: http://www.fda.gov/cdrh/pdf/p980022s011.html. Accessed April 27, 2006.
Medtronic, Inc. Web site. Medtronic receives FDA approval for the world’s first insulin pump with real-time continuous glucose monitoring. Available at: http://wwwp.medtronic.com/ Newsroom/NewsReleaseDetails.do?itemId=1144875806140&lang=en_US. Accessed April 27, 2006.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med. 1993; 329: 977–986.
American Diabetes Association. Standards of medical care in diabetes—2006.Diabetes Care. 2006; 29(suppl 1): S4-S42.
Rudolf P, Bartelme A. A strategic action plan for achieving uncompromising “treat to target” in individuals with insulin-dependent diabetes: a report by the Center for Insulin-Dependent Diabetes Access Blue Ribbon Panel.Diabetes Technol Ther. 2005; 7: 755–767.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mastrototaro, J.J., Cooper, K.W., Soundararajan, G. et al. Clinical experience with an integrated continuous glucose sensor/insulin pump platform: A feasibility study. Adv Therapy 23, 725–732 (2006). https://doi.org/10.1007/BF02850312
Issue Date:
DOI: https://doi.org/10.1007/BF02850312